{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=40",
    "query": {
      "condition": "Advanced Non-small Cell Lung Cancer (NSCLC)",
      "page": 40
    },
    "page_size": 10
  },
  "pagination": {
    "page": 40,
    "page_size": 10,
    "total_count": 1796,
    "total_pages": 180,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=41&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=39&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T10:16:25.957Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01137968",
      "title": "Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "imetelstat",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Geron Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2010-05",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2016-01-26",
      "last_synced_at": "2026-10-16T10:16:25.957Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01137968"
    },
    {
      "nct_id": "NCT03050060",
      "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Kidney Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Renal Cell Cancer AJCC v7",
        "Stage IV Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nelfinavir Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-06-09",
      "completion_date": "2020-07-12",
      "has_results": true,
      "last_update_posted_date": "2022-06-22",
      "last_synced_at": "2026-10-16T10:16:25.957Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03050060"
    },
    {
      "nct_id": "NCT03102242",
      "title": "Atezolizumab Immunotherapy in Patients With Advanced NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance Foundation Trials, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 64,
      "start_date": "2017-11-01",
      "completion_date": "2022-10-01",
      "has_results": true,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-10-16T10:16:25.957Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Brewer",
          "state": "Maine"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03102242"
    },
    {
      "nct_id": "NCT02143466",
      "title": "AZD9291 in Combination With Ascending Doses of Novel Therapeutics",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Part A - AZD9291 in combination with AZD6094",
          "type": "DRUG"
        },
        {
          "name": "Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)",
          "type": "DRUG"
        },
        {
          "name": "Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)",
          "type": "DRUG"
        },
        {
          "name": "Part A - AZD9291 in combination with intermittent selumetinib",
          "type": "DRUG"
        },
        {
          "name": "Part A - AZD9291 in combination with MEDI4736",
          "type": "DRUG"
        },
        {
          "name": "Part B - AZD9291 in combination with AZD6094",
          "type": "DRUG"
        },
        {
          "name": "Part B - AZD9291 in combination with selumetinib",
          "type": "DRUG"
        },
        {
          "name": "Part B - AZD9291 in combination with MEDI4736",
          "type": "DRUG"
        },
        {
          "name": "Part C - AZD6094 monotherapy (Japan only)",
          "type": "DRUG"
        },
        {
          "name": "Part C - AZD9291 in combination with AZD6094 (Japan only)",
          "type": "DRUG"
        },
        {
          "name": "Part D - AZD9291 in combination with AZD6094",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 344,
      "start_date": "2014-08-05",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-16T10:16:25.957Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143466"
    },
    {
      "nct_id": "NCT00998166",
      "title": "A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2009-06",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-10-16T10:16:25.957Z",
      "location_count": 2,
      "location_summary": "Lake Success, New York • New York, New York",
      "locations": [
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00998166"
    },
    {
      "nct_id": "NCT05456256",
      "title": "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of Lung",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "LP-300",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lantern Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2023-03-01",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-16T10:16:25.957Z",
      "location_count": 6,
      "location_summary": "Beverly Hills, California • Fountain Valley, California • Los Alamitos, California + 3 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05456256"
    },
    {
      "nct_id": "NCT03993873",
      "title": "Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumors",
        "MET Gene Alterations"
      ],
      "interventions": [
        {
          "name": "elzovantinib (TPX-0022)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Turning Point Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2019-09-05",
      "completion_date": "2027-03-03",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-10-16T10:16:25.957Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Orange, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03993873"
    },
    {
      "nct_id": "NCT07094113",
      "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "KRAS Altered Advanced or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "AMG 410",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Panitumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 434,
      "start_date": "2025-07-31",
      "completion_date": "2031-04-20",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-16T10:16:25.957Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07094113"
    },
    {
      "nct_id": "NCT07485179",
      "title": "Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Initiation of pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Initiation of chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 770,
      "start_date": "2026-03-12",
      "completion_date": "2027-03-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-16T10:16:25.957Z",
      "location_count": 1,
      "location_summary": "Somerville, Massachusetts",
      "locations": [
        {
          "city": "Somerville",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07485179"
    },
    {
      "nct_id": "NCT05401110",
      "title": "Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Carotuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karen Reckamp, MD, MS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2023-09-15",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-16T10:16:25.957Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Torrance, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05401110"
    }
  ]
}